Skip to main navigation Skip to search Skip to main content

Ensuring antibiotic development, equitable availability and responsible use of effective antibiotics: recommendations for multisectoral action

  • Annelie A Monnier
  • , Jeroen Schouten
  • , Gianpiero Tebano
  • , Veronica Zanichelli
  • , Benedikt D Huttner
  • , Céline Pulcini
  • , Christine Årdal
  • , Stephan Harbarth
  • , Marlies E Hulscher
  • , Inge C Gyssens
  • Radboud University Medical Center
  • Hasselt University
  • Scientific Center for Quality of Healthcare (IQ healthcare), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Université de Lorraine, APEMAC, Nancy, France.
  • Infection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
  • Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
  • Université de Lorraine, CHRU-Nancy, Infectious Diseases Department, Nancy, France.
  • Norwegian Institute of Public Health, Oslo, Norway.
  • Faculty of Medicine, Research group of Immunology and Biochemistry, Hasselt University, Hasselt, Belgium.

Research output: Contribution to journalArticleAcademicpeer-review

7 Downloads (Pure)

Abstract

Antibiotic resistance is a growing threat to global public health. The WHO Global Action Plan on Antimicrobial Resistance recommends engaging multisectoral stakeholders to tackle the issue. However, so far, few studies have addressed barriers to antibiotic development, equitable availability and responsible antibiotic use from the perspective of stakeholders outside healthcare facilities or patient communities: the so-called third-party stakeholders. Third-party stakeholders include, inter alia, governments, regulatory agencies and professionals working in antibiotic research and development (R&D) and medical ethics. This viewpoint provides an overview of barriers to antibiotic development, equitable availability of effective antibiotics and their responsible use. The barriers were identified in an exploratory qualitative interview study with an illustrative sample of twelve third-party stakeholders. Next, recommendations to lift these barriers are presented together with examples of recently made progress. The recommendations should guide future antibiotic policies and multisectoral policy action.

Original languageEnglish
JournalClinical infectious diseases
DOIs
Publication statusE-pub ahead of print - 26 Sept 2018
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Ensuring antibiotic development, equitable availability and responsible use of effective antibiotics: recommendations for multisectoral action'. Together they form a unique fingerprint.

Cite this